EMA Upholds Rejection of Omeros’ Narsoplimab for Transplant Complication
European regulators confirmed a negative opinion on Omeros’ first-in-class TA-TMA therapy despite FDA approval and strong U.S. demand.
European regulators confirmed a negative opinion on Omeros’ first-in-class TA-TMA therapy despite FDA approval and strong U.S. demand.
Doctors see 35%–40% U.S. share; peak sales estimate raised to about $400 million.
First full quarter of YARTEMLEA delivers $28.5M net product sales and turns Omeros profitable on an adjusted basis in Q2 2026.
AstraZeneca’s Ultomiris Phase 3 miss in adult HSCT-TMA is a clear positive for Omeros’ Yartemlea, removing a key rival.
Omeros shares fell sharply after the CHMP gave a negative opinion on its drug narsoplimab for transplant-associated thrombotic microangiopathy. Company plans re-examination.
Omeros' (OMER) Yartemlea becomes the first FDA-approved drug for TA-TMA, a life-threatening complication affecting stem cell transplant patients, with launch planned for January 2026.